- Home
- EDF vs NYXH Comparison
EDF vs NYXH Comparison
Compare EDF & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDF | NYXH |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.0M | 161.9M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EDF | NYXH |
|---|---|---|
| Price | $5.21 | $1.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 100.1K | ★ 120.9K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.72 | $1.26 |
| 52 Week High | $5.67 | $6.87 |
Technical Indicators
Market Signals| Indicator | EDF | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 54.28 |
| Support Level | $5.15 | $1.28 |
| Resistance Level | $5.39 | $1.70 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 48.57 | 88.57 |
Price Performance
Historical ComparisonAbout EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.